Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company’s next phase of growth, Adam ...

(Reuters) - Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the ...

For the first time in decades, targeted therapies to treat cutaneous lupus erythematosus are advancing through the research ...

CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the first patient has been dosed in the global clinical study, TOPAZ-1. The Phase 3 study will ...

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus ...

UCB SA (OTC:UCBJY) (OTC:UCBJF) (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) on Thursday presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab ...

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE) Litifilimab was recently granted Breakthrough Therapy ...

Biogen Inc. (NASDAQ:BIIB) is one of the 11 most profitable NASDAQ stocks to buy now. On June 12, UCB and Biogen presented additional detailed results from the Phase 3 PHOENYCS GO study, evaluating ...

NEW YORK/CHICAGO (Reuters) - Genentech and Biogen Idec said on Tuesday that their drug Rituxan failed as a treatment for lupus in a closely-watched study, potentially dashing hopes of a significant ...

Sept 24 (Reuters) - Biogen (BIIB.O), opens new tab and Belgian partner UCB (UCB.BR), opens new tab said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The promising Phase 3 results ...